Clinical Trial Update: A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating fruquintinib in combination with gefitinib for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• gefinitib (gefitinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: NSCLC | Phase 2 | Status: COMPLETED